COYA · Coya Therapeutics, Inc.
Market Cap
$114.98M
Shares
23.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.59
Open$4.82
Day$4.55–4.82
52W close$3.78–7.36
Avg vol 30d139K
Short int1.1M · 4.5% float · 7.8d
Short vol45%
Last earningsJun 2, 2026
DataDec 2022–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−6%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−5%
trailing
YTD return
−21%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.51% of float · ▼ -1.4% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+124%
Y/Y
EPS growth
−30%
Y/Y
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.51% of float · ▼ -1.4% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $5 · 23%
Range high $7
vs 200-day avg -6%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COYA
this stock
Coya Therapeutics, Inc.
|
$114.98M | -20.9% | +123.6% | — | 4.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COYA | -5.8% | +9.6% | -5.2% | +9.6% | -20.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -6.2% | +6.6% | -18.6% | +6.6% | -33.7% |
Key facts
CIK
1835022
CUSIP
22407B108
13F (30d)
49 filings
49 filers
Visit website
Investor relations